Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961

Roger J. Packer, Tianni Zhou, Emi Holmes, Gilbert Vezina, and Amar Gajjar

The purpose of the trial was to determine the survival and incidence of secondary tumors in children with medulloblastoma receiving radiotherapy plus chemotherapy. Three hundred seventy-nine eligible patients with nondisseminated medulloblastoma between the ages of 3 and 21 years were treated with 2340 cGy of craniospinal and 5580 cGy of posterior fossa irradiation. Patients were randomized between postradiation cisplatin and vincristine plus either CCNU or cyclophosphamide. Survival, pattern of relapse, and occurrence of secondary tumors were assessed. Five- and 10-year event-free survivals were 81 ± 2% and 75.8 ± 2.3%; overall survivals were 87 ± 1.8% and 81.3 ± 2.1%. Event-free survival was not impacted by chemotherapeutic regimen, sex, race, age at diagnosis, or gender. Seven patients had disease relapse beyond 5 years after diagnosis; relapse was local in 4 patients, local plus supratentorial in 2, and supratentorial alone in 1. Fifteen patients experienced secondary tumors as a first event at a median time of 5.8 years after diagnosis (11 >5 y postdiagnosis). All non-CNS solid secondary tumors (4) occurred in regions that had received radiation. Of the 6 high-grade gliomas, 5 occurred >5 years postdiagnosis. The estimated cumulative 10-year incidence rate of secondary malignancies was 4.2% (1.9%–6.5%). Few patients with medulloblastoma will relapse ≥5 years postdiagnosis; relapse will occur predominantly at the primary tumor site. Patients are at risk for development of secondary tumors, many of which are malignant gliomas. This may become an increasing issue as more children survive.

Keywords: chemotherapy, medulloblastoma, radiotherapy, secondary tumors.

Reported figures on event-free survival (EFS) and overall survival (OS) have slowly risen over the past 2 decades in pediatric cases of medulloblastoma, with multiple studies reporting 3- to 5-year EFS and OS rates of >70% in children with nondisseminated disease at time of diagnosis.1–5 Potential reasons for this apparent improvement in survival have been the routine employment of more aggressive surgery; more refined preoperative evaluations, resulting in a more pristine group of children with nondisseminated disease; and the use of adjuvant chemotherapy during and after radiotherapy.1–5 In past reports, especially those describing children receiving radiotherapy alone, late relapses, arbitrarily those occurring >5 years following diagnosis, were frequently reported.6–8 In addition, the frequency and impact of secondary tumors on both EFS and OS have been poorly characterized in children surviving medulloblastoma.6–8

In 2006, the results were reported of a phase III study of reduced-dose craniospinal radiation therapy (2400 cGy), standard local boost radiotherapy (total dose 5580 cGy), and adjuvant chemotherapy consisting of vincristine during radiotherapy and 1 of 2 cisplatin-containing postradiotherapy regimens.5 Five-year EFS and OS in this cohort of 379 patients were >80%, and the chemotherapy regimen received did not affect outcome. Since this initial report, both secondary
Methods

Between December 1996 and December 2000, 421 patients with medulloblastoma were entered on our study. To be eligible, patients had to have histologically confirmed medulloblastoma and be between the ages of 3 and 21 years, inclusive, at the time of diagnosis. Patients were to have no evidence of disseminated disease on MRI of the entire brain and spine performed pre- or postoperatively or on cytological examination of lumbar cerebrospinal fluid performed between 5 days of surgery and the onset of radiation. Patients were to have <1.5 cm$^2$ of residual tumor on postoperative imaging performed within 21 days, preferably within 72 h, of surgery. Patients with brainstem involvement were eligible for the study. Treatment must have begun within 31 days of definitive surgery. All institutions participating in this study had received approval from their institutional review boards, and age-appropriate informed consent/assent was obtained from each patient/parent/guardian.

Preoperative and postoperative MRI studies were centrally analyzed for 409 (97%) of the 421 patients for evaluation of extent of disease and amount of postoperative residual disease. Eligibility was based on institutional review, except when central review revealed unequivocal evidence of dissemination or excess residual disease, in which case, for analysis, patients were considered ineligible. If, on central review, studies were considered incomplete or not interpretable because of movement or other artifacts, patients were considered incompletely assessable but remained eligible for analysis. Central pathologic review was performed on 358 (85%) of the cohort by 1 of 2 neuropathologists. After central review, 379 patients (including 66 who, on evaluation, had no evidence of excess residual or metastatic disease but whose studies could not be fully evaluated because of poor quality or incompleteness of submission) were deemed eligible for analysis. Patient characteristics have been noted in a previous report.

Treatment

A dose of 2340 cGy of craniospinal radiation with a posterior fossa boost of 3240 cGy (total dose 5580 cGy) was prescribed in fractions of 180 cGy per day, 5 days per week. Treatment to the craniospinal axis was not to exceed 20 days, and the entire treatment was to be completed within 51 days. The boost volume included the entire posterior fossa with a 1-cm margin around the tentorium or the tumor. Both parallel opposing fields and conformal radiation therapy techniques were allowed. Spinal treatment was as outlined previously.

After surgery, eligible patients were randomized to receive either 8 cycles of regimen A or regimen B of chemotherapy, as previously described (see Fig. 1). Patients on both regimens were treated with weekly vincristine during radiotherapy (1.5 mg/m$^2$, maximum 2 mg, maximum 8 doses). Regimen A consisted of CCNU, cisplatin, and vincristine. Regimen B consisted of cisplatin, cyclophosphamide, and vincristine. Dose modifications for toxicity were as have been previously published.

Statistical Consideration

Patients were randomly assigned to 1 of the 2 experimental regimens at the time of study enrollment, stratified by age and brainstem involvement. The primary endpoint for analysis was time to a treatment-failure event (EFS) measured from the time of study enrollment. An event was defined as death from any cause, or the first occurrence of relapse, progressive disease, or development of a secondary tumor. The secondary endpoint was time to death from any cause or the first occurrence of, from which actuarial survival probability was computed. (Refer to the original article for details of statistical design of the trial.) Nonparametric EFS and survival curves were computed using product-limit (Kaplan–Meier) estimates, with standard errors via the Greenwood formula. Cumulative incidence of secondary tumors over time was calculated by the method proposed by Gray. Fisher’s exact test was used to detect
the relationship between years of relapse and the type of relapse.

Secondary tumors and relapse determinations.—
Patients were considered to have relapse or secondary tumors based on institutional determinations. All neuroradiographic studies demonstrating relapse or secondary tumors were centrally received. Pathologic confirmation of a secondary tumor was mandatory for inclusion, but pathologies were not centrally reviewed. As regards determining tumor relapse, pathologic confirmation was not mandatory and relapse could be diagnosed based on neuroradiographic interpretation by the treating institution.

Results

Overall Outcome

Data collection was halted 10 years after entry of the last patient on study. At time of analysis of the 379 eligible patients, the median follow-up for the 312 patients who were alive was 9.7 years (range, 0.2–13.7 y). Sixty-eight patients experienced tumor progression and 5 had death as first event; 58 have died to date. Late disease progression occurring 5 years after treatment occurred in 7 patients, 6 of whom died. The mean age at initial diagnosis of those developing late tumor relapse was 6.8 years. Two relapsed at an age later than their age at diagnosis plus 9 months. Fifteen developed secondary tumors—of these, 11 occurred more than 5 years after diagnosis, and 9 patients died (see Table 2).

For the cohort of 379 patients, 5- and 10-year EFSs were $81 \pm 2.0\%$ and $75.8 \pm 2.3\%$, respectively. Five- and 10-year OSs were $87 \pm 1.8\%$ and $81.3 \pm 2.1\%$, respectively (see Fig. 2). As noted in the original article, EFS did not differ between patients treated with regimen A and those treated with regimen B (see Fig. 3)—10-year EFS for regimen A was $74 \pm 3\%$ compared with $78 \pm 3.2\%$ for regimen B ($P = .24$). Moreover, EFS and OS were not impacted by sex, race, age at diagnosis, gender, brainstem involvement, extent of resection, or histologic evidence of diffuse or focal anaplasia.

Pattern of Disease Relapse

The pattern of disease relapse in patients on this study is as noted in Table 1. In the 7 patients with late relapse, pattern of relapse, as determined by the treating institution, was local in 4, local plus supratentorial in 2, and supratentorial alone in 1. Of these patients at time of initial entry to study, 5 had “total” resections and 2 “subtotal” resections. Of the 2 with subtotal initial resections, 1 failed locally and distally, and the second distally alone. On central review, the patient with a supratentorial-alone relapse had findings (radiographic) consistent with infiltrating glioma; however, the patient was not biopsied at relapse. For the purposes of this report, the patient is still considered a “late” relapse, as patients were classified per treating-institution diagnosis, unless there was clear pathologic evidence to document a different histology. In contrast, patients who relapsed earlier than 5 years from diagnosis had predominantly at least some component of disseminated relapse, with only 16% of patients having local relapse alone compared with 57% of patients with late relapse (Fisher’s exact test $P = .029$). Spinal involvement, either alone or in combination with local relapse, which was commonly seen in those relapsing before 5 years of age, was not seen in those relapsing later.
Secondary Tumors

Fifteen patients experienced secondary tumors as a first event; 8 were on regimen A and 7 on regimen B. The median time to secondary tumor was 5.8 years; 4 occurred <5 years and 11 >5 years postdiagnosis, as shown in Table 2. Patients with secondary tumors were diagnosed at a median of 5.6 years postdiagnosis (range, 3.1–16.8 y). There was no significant difference in the incidence of secondary tumors in children older than 5 years at diagnosis compared with younger children. There was also no significant difference between the 2 randomized arms. The estimated cumulative incidence rate of secondary tumors at 5 and 10 years for the entire cohort was 1.1% (95% CI: 0.0%–2.3%) and 4.2% (95% CI: 1.9%–6.5%), respectively (see Fig. 4). Nine patients with secondary tumors died; 6 of the 9 were on regimen A (the CCNU-containing arm). One child with glioblastoma multiforme, who was alive at the time of this report, had been followed for 1.18 months and had been treated in the cyclophosphamide arm of the study. One child, diagnosed with a secondary “pilocytic astrocytoma” of the brainstem, died secondary to the tumor within 1 year of diagnosis (central histopathologic review was not performed). The child with basal cell carcinomas developing within the radiotherapy field was diagnosed with Gorlin’s syndrome at time of development of the basal cell tumors. Of the 4 patients with non-CNS solid tumors, 2 had thyroid-region tumors, 1 had an osteosarcoma in the temporal bone, and 1 had a spindle cell sarcoma in the nasal region. Thus, all developed solid tumors in regions that would have received at least scatter radiation.

<table>
<thead>
<tr>
<th>Time of Secondary Tumor</th>
<th>Time after Treatmenta (y)</th>
<th>Regimen</th>
<th>Secondary Tumor Type</th>
<th>Life Status</th>
<th>Time since Last Seenb (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5 y</td>
<td></td>
<td></td>
<td>Precursor T-cell lymphoblastic leukemia</td>
<td>Dead</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>3.2</td>
<td>B</td>
<td>Glioblastoma, NOS</td>
<td>Dead</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>3.7</td>
<td>A</td>
<td>Basal cell carcinoma, NOS (Gorlin’s)</td>
<td>Alive</td>
<td>8.16</td>
</tr>
<tr>
<td></td>
<td>4.8</td>
<td>A</td>
<td>Spindle cell carcinoma</td>
<td>Alive</td>
<td>1.67</td>
</tr>
<tr>
<td>&gt;5 y</td>
<td></td>
<td></td>
<td>Glioma, malignant</td>
<td>Dead</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>5.3</td>
<td>A</td>
<td>Glioblastoma, NOS</td>
<td>Dead</td>
<td>0.56</td>
</tr>
<tr>
<td></td>
<td>5.7</td>
<td>A</td>
<td>Osteosarcoma, NOS</td>
<td>Dead</td>
<td>1.28</td>
</tr>
<tr>
<td></td>
<td>5.8</td>
<td>A</td>
<td>Myelodysplastic syndrome, NOS</td>
<td>Dead</td>
<td>6.87</td>
</tr>
<tr>
<td></td>
<td>6.4</td>
<td>B</td>
<td>Myelodysplastic syndrome, NOS</td>
<td>Alive</td>
<td>0.76</td>
</tr>
<tr>
<td></td>
<td>6.5</td>
<td>B</td>
<td>Pilocytic astrocytoma</td>
<td>Dead</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>8.2</td>
<td>B</td>
<td>Papillary adenocarcinoma, NOS (thyroid)</td>
<td>Alive</td>
<td>1.07</td>
</tr>
<tr>
<td></td>
<td>9.2</td>
<td>B</td>
<td>Glioblastoma multiforme</td>
<td>Dead</td>
<td>2.37</td>
</tr>
<tr>
<td></td>
<td>9.2</td>
<td>B</td>
<td>Glioblastoma multiforme</td>
<td>Alive</td>
<td>1.18</td>
</tr>
<tr>
<td></td>
<td>10.1</td>
<td>A</td>
<td>Papillary carcinoma, follicular (thyroid)</td>
<td>Alive</td>
<td>2.79</td>
</tr>
<tr>
<td></td>
<td>10.3</td>
<td>A</td>
<td>Glioma, malignant</td>
<td>Dead</td>
<td>0.51</td>
</tr>
</tbody>
</table>

Abbreviation: NOS, not otherwise specified.

aTime between initial diagnosis and development of the secondary tumor.

bTime between diagnosis of the secondary tumor and when last seen.

Discussion

The long-term results seen in this group of patients receiving radiotherapy and adjuvant chemotherapy, during and following radiotherapy, are both reassuring and cautionary. Ten-year EFS and OS rates of ~75%–80% are encouraging and compare favorably with survival rates reported in series utilizing radiation therapy alone or preradiation chemotherapy.2,4,5,9 Prospective randomized trials comparing radiation therapy alone to radiation plus chemotherapy have not been performed; however, the best reported survival rates at 5 and 10 years for children with nondisseminated medulloblastoma receiving radiotherapy alone have ranged between 50% and 65%, even with the use of higher...
of secondary tumors in children with brain tumors and is associated with increased relative risk for development of secondary tumors, especially those occurring >5 years from diagnosis and treatment. In our series, all solid non-CNS secondary tumors occurred either within the radiation therapy portal or in regions where scatter radiation was likely (thyroid, nasal region, and temporal bone). However, the exact incidence of these secondary tumors is difficult to glean from studies, and for children with medulloblastoma, the incidence has been estimated to be in the 1%–2% range. In retrospective reviews, the incidence of secondary tumors has been noted to be somewhat less after radiation therapy alone (in the 1% range at 10 years) or is not mentioned at all. In a recent prospective series from Germany of 280 patients administered either sandwich pre- and postradiation chemotherapy or postradiation chemotherapy, 12 patients developed secondary tumors, including 3 with high-grade gliomas; 8 of the 12 tumors were noted in patients who received the more aggressive sandwich chemotherapy, using similar drugs to those used in this series. In an analysis of the Surveillance Epidemiology and End Results data, a higher incidence of secondary tumors was noted in children surviving brain tumors treated after 1985 compared with those treated between 1979 and 1984, even when controlling for the use of radiation. The authors suggest that this might be due to the use of more aggressive chemotherapy in the later eras. The Childrens Cancer Survivor Study found a trend but not a statistically significant relationship between an increased occurrence of secondary tumors and treatment in the later era, compared with those treated earlier. It should be noted that although chemotherapy was used to some extent in the early 1980s, it has been increasingly employed since and is now considered by most a standard component of treatment for all children >3 years of age with medulloblastoma. Also, chemotherapeutic regimens employing potentially mutagenic alkylating agents, including in some cases etoposide, have been intensified over the past decade, raising the possibility that more secondary tumors may occur. On the other hand, those same studies used lower-dose craniospinal radiotherapy, and increased total doses of radiotherapy have been related to a higher incidence of secondary brain cancer. It remains to be seen whether the use of more focused radiotherapeutic techniques, such as proton beam irradiation, will in the future reduce the incidence of radiation-associated non-CNS secondary tumors.

Younger age at time of radiation has been related to a higher likelihood of development of a secondary tumor, but the results of this study do not show a relationship. Patients specifically developing high-grade gliomas were a median of 5.8 years of age at initial diagnosis (range, 3.7–10.8 y).

In the cohort of patients treated in this study, the majority of secondary tumors, especially those occurring >5 years postdiagnosis, have been highly aggressive, with 5 malignant gliomas, 1 osteosarcoma, and 2 myelodysplastic syndromes. The literature and our experience would suggest that those patients with high-grade gliomas will rarely respond to treatment or survive,
making occurrence of this complication even more devastat ing.12,18 Diagnosis of secondary malignant brain tumors in children with medulloblastoma is challenging, especially when they occur in the brainstem or similar deep-seated areas, and distinction between tumor recurrence and a secondary tumor can be impossible without histologic confirmation. Complicating diagnosis further is the difficulty of distinguishing small-cell gliomas from medulloblastomas that have undergone extensive glial differentiation, even when tissue is available for analysis. With all these considerations, it is impossible to determine whether this worrisome incidence of secondary tumors in this and other series evaluating patients with medulloblastoma receiving radiotherapy and chemotherapy is due to a true rise in incidence or better ascertainment. Also, in the present series, no meningiomas have been noted, and it is likely that as the survivor cohort ages, this tumor type will become prevalent.16,19,20

In conclusion, the updated results of this study demonstrate that the vast majority of children with nondisseminated medulloblastomas treated with radiation and receiving the chemotherapeutic regimens used in this study, during and after radiation therapy, will survive relapse-free. A small proportion of patients will relapse ≥5 years postdiagnosis, and in almost all, relapse will occur at the primary site. Patients are also at risk for development of secondary tumors including, but not limited to, tumors of the central nervous system, and long-term follow-up strategies must take this into account.

Conflict of interest statement. None declared.

Funding

This work was supported by the Chair’s Grant U10 CA98543-08 Statistics and Data Center Grant U10 CA98413-08 of the Children’s Oncology Group from the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH.

References


